^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Halaven (eribulin mesylate)

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Eisai, Knight Therap, Shenzhen Kexing Pharma
    Drug class:
    Microtubule inhibitor
    Related drugs:
    1d
    OptiTROP Breast02: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=376, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)
    3d
    Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review. (PubMed, Front Oncol)
    Due to age, comorbidities, and unresectable disease, first-line therapy with anlotinib was initiated. This case suggests that eribulin may provide durable disease control and is a well-tolerated therapeutic option for elderly patients with inoperable retroperitoneal WDLPS, providing preliminary evidence for its potential to achieve long-term tumor stability and maintain quality of life in this vulnerable population. Multidisciplinary assessment and individualized treatment strategies remain essential in optimizing outcomes.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    4d
    MEDOPP0776: PHASE?IB/II STUDY TO EVALUATE SAFETY AND PRELIMINARY EFFICACY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB AND CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER (The JAZMINE Study) (2025-524613-89-00)
    P1/2, N=129, Not yet recruiting, Medica Scientia Innovation Research S.L.
    New P1/2 trial
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • Halaven (eribulin mesylate) • Tukysa (tucatinib) • dexamethasone • Ziihera (zanidatamab-hrii)
    10d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=56 --> 792
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    11d
    A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P3 trial
    |
    capecitabine • Halaven (eribulin mesylate) • bulumtatug fuvedotin (9MW2821)
    17d
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Halaven (eribulin mesylate)
    17d
    A multicenter, single-arm phase II clinical study of eribulin combined with inituzumab and pyrotinib in the treatment of HER2-positive advanced breast cancer (ChiCTR2600121825)
    P2, N=76, Recruiting, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Irene (pyrotinib) • Halaven (eribulin mesylate) • TheraCIM (nimotuzumab)
    17d
    Trastuzumab and pertuzumab in combination with eribulin mesylate as neoadjuvant therapy for early or locally advanced HER2-positive breast cancer: a prospective, single-arm, phase II clinical trial (ChiCTR2600120346)
    P4, N=40, Recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Halaven (eribulin mesylate)
    18d
    NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way. (PubMed, iScience)
    In vivo, eribulin or NUP62 silencing significantly suppressed tumor growth in xenograft models. Our findings establish the NUP62-KEAP1-NRF2 axis as a master regulator of ferroptosis in BC, positioning eribulin as a promising therapeutic agent for NUP62-high tumors.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NUP62 (Nucleoporin 62)
    |
    Halaven (eribulin mesylate)
    22d
    Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. (PubMed, JTO Clin Res Rep)
    FZEC demonstrated modest antitumor activity, and observed AEs were generally manageable in patients with heavily pretreated NSCLC. NCT03386942.
    P1 data • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
    24d
    A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care (clinicaltrials.gov)
    P3, N=364, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P3 trial
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    1m
    MBC-EA: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (clinicaltrials.gov)
    P2, N=52, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)